NUVB · Nuvation Bio Inc.
$6.49
-0.92% last session
End-of-day data · updated 2026-07-25
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-107.0
Dividend yield
—
Beta
1.53
Avg volume
6M
Employees
0K
2D change
-1.08%
5D change
2.56%
10D change
8.81%
30D change
10.50%
60D change
36.89%
MTD change
18.45%
YTD change
-28.35%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NUVB
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-27
Latest call per bank · past 12 months
RBC Capital
Outperform$19.00
+192.8% vs priceUBS
Neutral$7.00
+7.9% vs priceJefferies
Buy$10.00
+54.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-27 | HC Wainwright & Co. | Maintains | Buy | $17.00 → $21.00 |
| 2026-07-23 | Wedbush | Reiterates | Outperform | $11.00 |
| 2026-07-07 | RBC Capital | Maintains | Outperform | $20.00 → $19.00 |
| 2026-07-07 | Truist Securities | Maintains | Buy | $12.00 → $13.00 |
| 2026-05-05 | RBC Capital | Reiterates | Outperform | $20.00 |
| 2026-05-05 | Wedbush | Reiterates | Outperform | $11.00 |
| 2026-05-05 | HC Wainwright & Co. | Reiterates | Buy | $17.00 |
| 2026-04-16 | Wedbush | Reiterates | Outperform | $11.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 65 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 22.2% above the 50-day MA ($5.31).
- Price vs 200-day MA: Trading 15.5% above the 200-day MA ($5.62).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.05) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($2.23) and high ($9.54).
NUVB Price Chart
Loading chart for NUVB…
Fundamentals
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.